Disclosure Mike Kirby has received funding for research, conference attendance, lecturing and advice from the pharmaceutical industry including, Pfizer, MSD, GSK, Astellas, Bayer, Lilly and Takeda.
Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis
Article first published online: 25 APR 2013
© 2013 John Wiley & Sons Ltd
International Journal of Clinical Practice
Volume 67, Issue 7, pages 606–618, July 2013
How to Cite
Kirby, M., Chapple, C., Jackson, G., Eardley, I., Edwards, D., Hackett, G., Ralph, D., Rees, J., Speakman, M., Spinks, J. and Wylie, K. (2013), Erectile dysfunction and lower urinary tract symptoms: a consensus on the importance of co-diagnosis. International Journal of Clinical Practice, 67: 606–618. doi: 10.1111/ijcp.12176
Chris Chapple has worked as a consultant to American Medical Systems and Lilly, as a consultant and researcher to ONO, as a consultant, researcher and speaker for Allergan, Astellas, Pfizer and Recordati.
Graham Jackson has advised Lilly, Pfizer and Bayer, and talked at sponsored educational meetings.
Ian Eardley has worked as a consultant and speaker for Lilly, Bayer, Pfizer and Allergan.
David Edwards has received funding for research, lecturing, advisory board and conference attendance from the pharmaceutical industry including Bayer, GSK, Lilly, Pfizer, ProStakan and Owen Mumford.
Geoff Hackett is an occasional speaker and advisory board member for Lilly and Bayer.
Jon Rees has worked as a consultant to Lilly, GSK and Pfizer, and has received speaker funding from GSK & Lilly.
David Ralph has worked as a consultant to Lilly, Axillium, Coloplast and American Medical Systems. Mark Speakman has received research funding from Allergan, Astellas, GSK and Genprobe. He has been a lecturer for Astellas, GSK, Lilly and Genprobe.
Julian Spinks has worked as a consultant to Pfizer, GSK, Astellas Orion and Boehringer Ingelheim, and received speaker fees from Pfizer and Astellas.
Kevan Wylie has no conflicts of interest.
Consensus statement: Evidence suggests a strong link between erectile dysfunction and lower urinary tract symptoms in men that is independent of age. Co-diagnosis of these conditions is therefore important.
Linked Comment: Rosenberg et al. Int J Clin Pract 2013; 67: 599–600.
- Issue published online: 13 JUN 2013
- Article first published online: 25 APR 2013
- Manuscript Accepted: 22 MAR 2013
- Manuscript Received: 10 DEC 2012
Despite differences in design, many large epidemiological studies using well-powered multivariate analyses consistently provide overwhelming evidence of a link between erectile dysfunction (ED) and lower urinary tract symptoms (LUTS). Preclinical evidence suggests that several common pathophysiological mechanisms are involved in the development of both ED and LUTS. We recommend that patients seeking consultation for one condition should always be screened for the other condition. We propose that co-diagnosis would ensure that patient management accounts for all possible co-morbid and associated conditions. Medical, socio-demographic and lifestyle risk factors can help to inform diagnoses and should be taken into consideration during the initial consultation. Awareness of risk factors may alert physicians to patients at risk of ED or LUTS and so allow them to manage patients accordingly; early diagnosis of ED in patients with LUTS, for example, could help reduce the risk of subsequent cardiovascular disease. Prescribing physicians should be aware of the sexual adverse effects of many treatments currently recommended for LUTS; sexual function should be evaluated prior to commencement of treatment, and monitored throughout treatment to ensure that the choice of drug is appropriate.